Global Cord Blood Banking Market 2020 with Analysis of 44 Industry Players – PRNewswire
By daniellenierenberg
DUBLIN, Sept. 2, 2020 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.
This report presents the number of cord blood units stored in inventory by the largest cord blood banks worldwide and the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell (HSC) transplantation. Although cord blood is now used to treat more than 80 different diseases, this number could substantially expand if applications related to regenerative medicine start receiving approvals in major healthcare markets worldwide.
From the early 1900s through the mid-2000s, the global cord blood banking industry expanded rapidly, with companies opening for business in all major markets worldwide. From 2005 to 2010, the market reached saturation and stabilized.
Then, from 2010 to 2020, the market began to aggressively consolidate. This has created both serious threats and unique opportunities within the industry.
Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide and expanding applications for cell-based therapies. In particular, MSCs from cord tissue (and other sources) are showing intriguing promise in the treatment and management of COVID-19.
Cord Blood Industry Trends
Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.
Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 270,000 stem cell units by the end of 2020. It now owns a half dozen cord blood banks, as well as a dental stem cell storage company.
Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife' reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia but in the world.
The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.
Cord Blood Expansion Technologies
Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.
Key strategies being explored for this purpose include:
Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.
Cord Blood Banking by Region
Within the United States, most of the market share is controlled by three major players: Cord Blood Registry (CBR), Cryo-Cell, and ViaCord. CBR has been traded twice, once in 2015 to AMAG Pharmaceuticals for $700 million and again in 2018 to GI Partners for $530 million. CBR also bought Natera's Evercord Cord Blood Banking business in September 2019. In total, CBR controls over 900,000 cord blood and tissue samples, making it one of the largest cord blood banks worldwide.
In China, the government controls the industry by authorizing only one cord blood bank to operate within each province, and official government support, authorization, and permits are required. Importantly, the Chinese government announced in late 2019 that it will be issuing new licenses for the first time, expanding from the current 7 licensed regions for cord blood banking to up to 19 regions, including Beijing.
In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region. In Ecuador, the government created the first public cord blood bank and instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for private banks, forcing most out of business.
Recently, India's Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells - leaving only umbilical cord blood banking as permitted and licensed within the country.
While market factors vary by geography, it is crucial to have a global understanding of the industry, because research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics within your region is not sufficient for making strategic, informed, and profitable decisions.
Overall, the report provides the reader with the following details and answers the following questions:
1. Number of cord blood units cryopreserved in public and private cord blood banks globally2. Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells3. Utilization of cord blood cells in clinical trials for developing regenerative medicines4. The decline of the utilization of cord blood cells in HSC transplantations since 20055. Emerging technologies to influence the financial sustainability of public cord blood banks6. The future scope for companion products from cord blood7. The changing landscape of cord blood cell banking market8. Extension of services by cord blood banks9. Types of cord blood banks10. The economic model of public cord blood banks11. Cost analysis for public cord blood banks12. The economic model of private cord blood banks13. Cost analysis for private cord blood banks14. Profit margins for private cord blood banks15. Pricing for processing and storage in private banks16. Rate per cord blood unit in the U.S. and Europe17. Indications for the use of cord blood-derived HSCs for transplantations18. Diseases targeted by cord blood-derived MSCs in regenerative medicine19. Cord blood processing technologies20. Number of clinical trials, number of published scientific papers and NIH funding for cord blood research21. Transplantation data from different cord blood registries
Key questions answered in this report are:
1. What are the strategies being considered for improving the financial stability of public cord blood banks?2. What are the companion products proposed to be developed from cord blood?3. How much is being spent on processing and storing a unit of cord blood?4. How much does a unit of cryopreserved cord blood unit fetch on release?5. Why do most public cord blood banks incur a loss?6. What is the net profit margin for a private cord blood bank?7. What are the prices for processing and storage of cord blood in private cord blood banks?8. What are the rates per cord blood units in the U.S. and Europe?9. What are the revenues from cord blood sales for major cord blood banks?10. Which are the different accreditation systems for cord blood banks?11. What are the comparative merits of the various cord blood processing technologies?12. What is to be done to increase the rate of utilization of cord blood cells in transplantations?13. Which TNC counts are preferred for transplantation?14. What is the number of registered clinical trials using cord blood and cord tissue?15. How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?17. What is the share of cord blood cells used for transplantation from 2000 to 2020?18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?19. Which are the top ten countries for donating cord blood?20. What are the diseases targeted by cord blood-derived MSCs within clinical trials?
Key Topics Covered
1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary1.3 Introduction1.3.1 Cord Blood: An Alternative Source for HPSCs1.3.2 Utilization of Cord Blood Cells in Clinical Trials1.3.3 The Struggle of Cord Blood Banks1.3.4 Emerging Technologies to Influence Financial Sustainability of Banks1.3.4.1 Other Opportunities to Improve Financial Stability1.3.4.2 Scope for Companion Products1.3.5 Changing Landscape of Cord Blood Cell Banking Market1.3.6 Extension of Services by Cord Blood Banks
2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW2.1 Cord Blood Banking (Stem Cell Banking)2.1.1 Public Cord Blood Banks2.1.1.1 Economic Model of Public Cord Blood Banks2.1.1.2 Cost Analysis for Public Banks2.1.1.3 Relationship between Costs and Release Rates2.1.2 Private Cord Blood Banks2.1.2.1 Cost Analysis for Private Cord Blood Banks2.1.2.2 Economic Model of Private Banks2.1.3 Hybrid Cord Blood Banks2.2 Globally Known Cord Blood Banks2.2.1 Comparing Cord Blood Banks2.2.2 Cord Blood Banks in the U.S.2.2.3 Proportion of Public, Private and Hybrid Banks2.3 Percent Share of Parents of Newborns Storing Cord Blood by Country/Region2.4 Pricing for Processing and Storage in Commercial Banks2.4.1 Rate per Cord Blood Unit in the U.S. and Europe2.5 Cord Blood Revenues for Major Cord Blood Banks
3. CORD BLOOD BANK ACCREDITATIONS3.1 American Association of Blood Banks (AABB)3.2 Foundation for the Accreditation of Cellular Therapy (FACT)3.3 FDA Registration3.4 FDA Biologics License Application (BLA) License3.5 Investigational New Drug (IND) for Cord Blood3.6 Human Tissue Authority (HTA)3.7 Therapeutic Goods Act (TGA) in Australia3.8 International NetCord Foundation3.9 AABB Accredited Cord Blood Facilities3.10 FACT Accreditation for Cord Blood Banks
4. APPLICATIONS OF CORD BLOOD CELLS4.1 Hematopoietic Stem Cell Transplantations with Cord Blood Cells4.2 Cord Cells in Regenerative Medicine
5. CORD BLOOD PROCESSING TECHNOLOGIES5.1 The Process of Separation5.1.1 PrepaCyte-CB5.1.2 Advantages of PrepaCyte-CB5.1.3 Treatment Outcomes with PrepaCyte-CB5.1.4 Hetastarch (HES)5.1.5 AutoXpress (AXP)5.1.6 SEPAX5.1.7 Plasma Depletion Method (MaxCell Process)5.1.8 Density Gradient Method5.2 Comparative Merits of Different Processing Methods5.2.1 Early Stage HSC Recovery by Technologies5.2.2 Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood5.2.3 Late Stage Recovery of HSCs from Cord Blood5.3 HSC (CD45+) Recovery5.4 Days to Neutrophil Engraftment by Technology5.5 Anticoagulants used in Cord Blood Processing5.5.1 Type of Anticoagulant and Cell Recovery Volume5.5.2 Percent Cell Recovery by Sample Size5.5.3 TNC Viability by Time Taken for Transport and Type of Anticoagulant5.6 Cryopreservation of Cord Blood Cells5.7 Bioprocessing of Umbilical Cord Tissue (UCT)5.8 A Proposal to Improve the Utilization Rate of Banked Cord Blood
6. CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING6.1 Cord Blood Cells for Research6.2 Cord Blood Cells for Clinical Trials6.2.1 Number of Clinical Trials involving Cord Blood Cells6.2.2 Number of Clinical Trials using Cord Blood Cells by Geography6.2.3 Number of Clinical Trials by Study Type6.2.4 Number of Clinical Trials by Study Phase6.2.5 Number of Clinical Trials by Funder Type6.2.6 Clinical Trials Addressing Indications in Children6.2.7 Select Three Clinical Trials Involving Children6.2.7.1 Sensorineural Hearing Loss (NCT02038972)6.2.7.2 Autism Spectrum (NCT02847182)6.2.7.3 Cerebral Palsy (NCT01147653)6.2.8 Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue6.2.9 UCB for Diabetes6.2.10 UCB in Cardiovascular Clinical Trials6.2.11 Cord Blood Cells for Auto-Immune Diseases in Clinical Trials6.2.12 Cord Tissue Cells for Orthopedic Disorders in Clinical Trials6.2.13 Cord Blood Cells for Other Indications in Clinical Trials6.3 Major Diseases Addressed by Cord Blood Cells in Clinical Trials6.4 Clinical Trials using Cord Tissue-Derived MSCs6.5 Ongoing Clinical Trials using Cord Tissue6.5.1 Cord Tissue-Based Clinical Trials by Geography6.5.2 Cord Tissue-Based Clinical Trials by Phase6.5.3 Cord Tissue-Based Clinical Trials by Sponsor Types6.5.4 Companies Sponsoring in Trials using Cord Tissue-Derived MSCs6.6 Wharton's Jelly-Derived MSCs in Clinical Trials6.6.1 Wharton's Jelly-Based Clinical Trials by Phase6.6.2 Companies Sponsoring Wharton's Jelly-Based Clinical Trials6.7 Clinical Trials Involving Cord Blood Expansion Studies6.7.1 Safe and Feasible Expansion Protocols6.7.2 List of Clinical Trials involved in the Expansion of Cord Blood HSCs6.7.3 Expansion Technologies6.8 Scientific Publications on Cord Blood6.9 Scientific Publications on Cord Tissue6.10 Scientific Publications on Wharton's Jelly-Derived MSCs6.11 Published Scientific Papers on Cord Blood Cell Expansion6.12 NIH Funding for Cord Blood Research
7. PARENT'S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING7.1 Undecided Expectant Parents7.2 The Familiar Cord Blood Banks Known by the Expectant Parents7.3 Factors Influencing the Choice of a Cord Blood Bank
8. CORD BLOOD: AS A TRANSPLANTATION MEDICINE8.1 Comparisons of Cord Blood to other Allograft Sources8.1.1 Major Indications for HCTs in the U.S.8.1.2 Trend in Allogeneic HCT in the U.S. by Recipient Age8.1.3 Trends in Autologous HCT in the U.S. by Recipient Age8.2 HCTs by Cell Source in Adult Patients8.2.1 Transplants by Cell Source in Pediatric Patients8.3 Allogeneic HCTs by Cell Source8.3.1 Unrelated Donor Allogeneic HCTs in Patients &lessThan;18 Years8.4 Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity8.4.1 Likelihood of Finding an Unrelated Cord Blood Unit for Patients &lessThan;20 Years8.5 Odds of using a Baby's Cord Blood8.6 Cord Blood Utilization Trends8.7 Number of Cord Blood Donors Worldwide8.7.1 Number of CBUs Stored Worldwide8.7.2 Cord Blood Donors by Geography8.7.2.1 Cord Blood Units Stored in Different Geographies8.7.2.2 Number of Donors by HLA Typing8.7.3 Searches Made by Transplant Patients for Donors/CBUs8.7.4 Types of CBU Shipments (Single/Double/Multi)8.7.5 TNC Count of CBUs Shipped for Children and Adult Patients8.7.6 Shipment of Multiple CBUs8.7.7 Percent Supply of CBUs for National and International Patients8.7.8 Decreasing Number of CBU Utilization8.8 Top Ten Countries in Cord Blood Donation8.8.1 HLA Typed CBUs by Continent8.8.2 Percentage TNC of Banked CBUs8.8.3 Total Number of CBUs, HLA-Typed Units by Country8.9 Cord Blood Export/Import by the E.U. Member States8.9.1 Number of Donors and CBUs in Europe8.9.2 Number of Exports/Imports of CBUs in E.U.8.10 Global Exchange of Cord Blood Units
9. CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY9.1 MSCs from Cord Blood and Cord Tissue9.1.1 Potential Neurological Applications of Cord Blood-Derived Cells9.1.2 Cord Tissue-Derived MSCs for Therapeutic use9.1.2.1 Indications Targeted by UCT-MSCs in Clinical Trials9.2 Current Consumption of Cord Blood Units by Clinical Trials9.3 Select Cord Blood Stem Cell Treatments in Clinical Trials9.3.1 Acquired Hearing Loss (NCT02038972)9.3.2 Autism (NCT02847182)9.3.3 Cerebral Palsy (NCT03087110)9.3.4 Hypoplastic Left Heart Syndrome (NCT01856049)9.3.5 Type 1 Diabetes (NCT00989547)9.3.6 Psoriasis (NCT03765957)9.3.7 Parkinson's Disease (NCT03550183)9.3.8 Signs of Aging (NCT04174898)9.3.9 Stroke (NCT02433509)9.3.10 Traumatic Brain Injury (NCT01451528)
10. MARKET ANALYSIS10.1 Public vs. Private Cord Blood Banking Market10.2 Cord Blood Banking Market by Indication
11. PROFILES OF SELECT CORD BLOOD BANKS11.1 AllCells11.1.1 Whole Blood11.1.2 Leukopak11.1.3 Mobilized Leukopak11.1.4 Bone Marrow11.1.5 Cord Blood11.2 AlphaCord LLC11.2.1 NextGen Collection System11.3 Americord Registry, Inc.11.3.1 Cord Blood 2.011.3.2 Cord Tissue11.3.3 Placental Tissue 2.011.4 Be The Match11.4.1 Hub of Transplant Network11.4.2 Partners of Be The Match11.4.3 Allogeneic Cell Sources in Be The Match Registry11.4.4 Likelihood of a Matched Donor on Be The Match by Ethnic Background11.5 Biocell Center Corporation11.5.1 Chorionic villi after Delivery11.5.2 Amniotic Fluid and Chorionic Villi during Pregnancy11.6 BioEden Group, Inc.11.6.1 Differences between Tooth Cells and Umbilical Cord Cells11.7 Biovault Family11.7.1 Personalized Cord Blood Processing11.8 Cell Care11.9 Cells4Life Group, LLP11.9.1 Cells4Life's pricing11.9.2 TotiCyte Technology11.9.3 Cord Blood Releases11.10 Cell-Save11.11 Center for International Blood and Marrow Transplant Research (CIBMTR)11.11.1 Global Collaboration11.11.2 Scientific Working Committees11.11.3 Medicare Clinical Trials and Studies11.11.4 Cellular Therapy11.12 Crio-Cell International, Inc.11.12.1 Advanced Collection Kit11.12.2 Prepacyte-CB11.12.3 Crio-Cell International's Pricing11.12.4 Revenue for Crio-Cell International11.13 Cord Blood Center Group11.13.1 Cord Blood Units Released11.14 Cordlife Group, Ltd.11.14.1 Cordlife's Cord Blood Release Track Record11.15 Core23 Biobank11.16 Cord Blood Registry (CBR)11.17 CordVida11.18 Crioestaminal11.18.1 Cord Blood Transplantation in Portugal11.19 Cryo-Cell International, Inc.11.19.1 Processing Method11.19.2 Financial Results of the Company11.20 CryoHoldco11.21 Cryoviva Biotech Pvt. Ltd11.22 European Society for Blood and Bone Marrow Transplantation (EBMT)11.22.1 EBMT Transplant Activity11.23 FamiCord Group11.24 GeneCell International11.25 Global Cord Blood Corporation11.25.1 The Company's Business11.26 HealthBaby Hong Kong11.26.1 BioArchive System Service Plan11.26.2 MVE Liquid Nitrogen System11.27 HEMAFUND11.28 Insception Lifebank11.29 LifebankUSA11.29.1 Placental Banking11.30 LifeCell International Pvt. Ltd.11.31 MiracleCord, Inc.11.32 Maze Cord Blood Laboratories11.33 New England Cord Blood Bank, Inc.11.34 New York Cord Blood Center (NYBC)11.34.1 Products11.34.2 Laboratory Services11.35 PacifiCord11.35.1 FDA-Approved Sterile Collection Bags11.35.2 AXP Processing System11.35.3 BioArchive System11.36 ReeLabs Pvt. Ltd.11.37 Smart Cells International, Ltd.11.38 Stem Cell Cryobank11.39 StemCyte, Inc.11.39.1 StemCyte Sponsored Clinical Trials11.39.1.1 Spinal Cord Injury Phase II11.39.1.2 Other Trials11.40 Transcell Biolife11.40.1 ScellCare11.40.2 ToothScell11.41 ViaCord11.42 Vita 34 AG11.43 World Marrow Donor Association (WMDA)11.43.1 Search & Match Service11.44 Worldwide Network for Blood & Marrow Transplantation (WBMT)
For more information about this report visit https://www.researchandmarkets.com/r/7bm9lx
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets Laura Wood, Senior Manager [emailprotected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
http://www.researchandmarkets.com
Continued here:
Global Cord Blood Banking Market 2020 with Analysis of 44 Industry Players - PRNewswire
- 001 Paralyzed rat walks with own stem cells in 11 wks. [Last Updated On: July 11th, 2011] [Originally Added On: July 11th, 2011]
- 002 Stem Cells for Spinal Cord Injury: Community Outreach San Diego 2011 - Trish Stressman [Last Updated On: August 9th, 2011] [Originally Added On: August 9th, 2011]
- 003 Non-controversial Stem Cells: Rationale for Clinical Use: Neil Riordan, Ph.D. - Miami, FL [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 004 Cure for blindness - retina repair using stem cells. Future health keynote speaker [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 005 Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- 006 William Rader MD - Paralyzed Spinal Cord Injury Patient Walks Again [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 007 Adult Stem Cell Sucess Stories - Laura Dominguez [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 008 Spinal Cord Injury Treatment With Stem Cells [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 009 Over Comes Spinal Cord Injury - No Surgery or Stem Cells http://www.releasetechnique.com [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- 010 Non-controversial Stem Cells: Rationale for Clinical Use - Dr. Neil Riordan [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- 011 Stem Cells Therapy for Spinal Cord Injury.flv [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- 012 Walking after Spinal Cord injury and Stem Cells [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 013 Stem Cells May Reverse Paralysis, Brain Damage, and Organ Failure [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 014 The Usefulness of Adult Olfactory Stem Cells in Spinal Cord Injury and Brain Injury [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 015 Stem cells for Parkinson's Disease, Spinal Cord Injury [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 016 Embryonal Stem Cells Promote Functional Recovery in Spinal Injured Animals [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 017 First Spinal-Cord Surgery With Stem Cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 018 Medra Inc - Paralyzed Spinal Cord Injury Patient Walks Again [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 019 Spinal Cord Injury - Embryonic Stem Cells - Dr. Keirstead [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 020 Stem cell treatment by Adiva Health Care India after Spinal Cord Injury [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 021 Embryonic Stem Cells Cure Spinal Cord Injury? [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- 022 Stem Cells for Spinal Cord Injury [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 023 Stem Cells and Neurogenesis [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 024 Stemcells come alive: Fix Mouse with severed spine ABCnews [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 025 The Spinal Cord Journey - Stem cell therapy stories from three spinal cord injury patients [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 026 Spinal Cord Injury patient 10 years after injury after Stem Cell Treatment [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 027 StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 028 The Promises of Neural Stem Cells in Motor Neuron Disease [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 029 Stem Cell Series: Part 3 [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 030 Christopher "Kit" Bond - Spinal Cord Injury Stem Cell Patient [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 031 Roman Reed: What all patient advocates at the World Stem Cell Summit should know [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- 032 Noah Stem Cell Transplant Day 3 [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- 033 Spinal Patient Receives Stem Cells in First Experimental Treatment [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- 034 Health and Home Stem-1 [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- 035 UK's first approved adult stem cell bank Oristem® explained [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- 036 Stem Cells: Hope, Hype and Progress - Session 1b [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- 037 Stem Cells: Hope, Hype and Progress - Session 3 - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 038 Human Trials of Embryonic Stem Cell Treatment Beginning - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 039 (Film Trailer) - The Spinal Cord Journey: Stem Cell Therapy Stories of Recovery - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- 040 Stem Cell Treatment for Spinal Cord Injury - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- 041 Public Symposium: The Stem Cell Promise: Moving to the Clinic - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- 042 Stem Cells: Hope, Hype and Progress - Session 1a - Video [Last Updated On: October 29th, 2011] [Originally Added On: October 29th, 2011]
- 043 Stem Cell Treatment for T-6 Spinal Cord Injury - Video [Last Updated On: October 29th, 2011] [Originally Added On: October 29th, 2011]
- 044 Tamara Marquis - SCI Stem Cell Patient - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- 045 Stem Cells - Treatment for Spinal Cord Injury - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- 046 Electro-Medicine : Biological Physics - Paralysis Spinal Chord Injury Treatment - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- 047 Biological Physics : Stem Cells - Paralyzed Spinal Cord Injury Patient Walks Again - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- 048 Innovative stem cell treatment for Spinal Cord Injuries - Video [Last Updated On: November 22nd, 2011] [Originally Added On: November 22nd, 2011]
- 049 Stem Cells Treatment for Spinal Cord Injuries, Successfully Results, Stem Therapy - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- 050 Gabi - SCI Stem Cell Patient - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- 051 Stem Cell Treatment for Spinal Cord Injury - Patient Interview - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 052 StemCellTV Daily Report-November 22, 2011 - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 053 Which Stem Cell Will Win The Race To Repair The Spinal Cord? - Video [Last Updated On: December 23rd, 2011] [Originally Added On: December 23rd, 2011]
- 054 China medical tourism--spinal cord injury--stem cells therapy - Video [Last Updated On: December 27th, 2011] [Originally Added On: December 27th, 2011]
- 055 MouseVideo-SCI - Video [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 056 Explaining stem cells - Video [Last Updated On: January 3rd, 2012] [Originally Added On: January 3rd, 2012]
- 057 China medical tourism--Spinal Injury--Stem Cell - Video [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- 058 Stem cell therapy at VMC - Video [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- 059 Breakthrough Spinal Cord Injury Treatment - Stem Cell Of America - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 060 Stem cell treatments change girl's life [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 061 Neuralstem Announces Closing of $5.2-Million Registered Direct Offering [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 062 Stem-cell scientists find right chemistry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 063 Panamanian-US Scientific Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- 064 Qatari students to present research on stem cells [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- 065 Bioethics Backlash [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- 066 Waisan Poon, "Clinical trial of umbilical cord blood stem cells in spinal cord injury" - Video [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- 067 Osamu Honmou, "Transplantation of bone marrow stem cells" - Video [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- 068 Dah-Ching Ding, "Human umbilical cord mesenchymal stem cells support prolonged expansion of... - Video [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- 069 Stem Cell Action Coalition Opposes Virginia Personhood Bill [Last Updated On: February 24th, 2012] [Originally Added On: February 24th, 2012]
- 070 Adding Six More, Omeros Now Has a Total of 33 Unlocked Orphan GPCRs in its Portfolio [Last Updated On: February 29th, 2012] [Originally Added On: February 29th, 2012]
- 071 It's not pulp fiction [Last Updated On: March 4th, 2012] [Originally Added On: March 4th, 2012]
- 072 Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells ... [Last Updated On: March 6th, 2012] [Originally Added On: March 6th, 2012]
- 073 Will StemCells Walk The Talk? [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- 074 Young aims for spinal injury 'cure' [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- 075 Doctor looks to China for spinal injury 'cure' [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- 076 Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- 077 Neuralstem Shows Solid Progress in Spinal Cord Neural Stem Cell Trial for ALS [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- 078 Oklahoma bill proposes umbilical cord blood bank [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- 079 Research suggests new therapeutic approach for spinal cord injury [Last Updated On: March 13th, 2012] [Originally Added On: March 13th, 2012]
- 080 Doctor looks to China for spinal injury ‘cure’ [Last Updated On: March 13th, 2012] [Originally Added On: March 13th, 2012]
